Phase 3, Double-Blind, Placebo-Controlled Study of Vemurafenib Versus Vemurafenib + Cobimetinib in Previously Untreated Brafv600 Mutation–Positive Patients with Unresectable Locally Advanced or Metastatic Melanoma (Nct01689519)Grant A. McArthur, Brigitte Dréno, Gabriella Liszkay et al.|Annals of Oncology|2014Cited by 3